Beyond Psychedelic Microdosing: Therapeutic Potential, Neuropharmacology, and Safety Considerations in Low-Dose Psychoactive Use

Microdosing and related low-dose psychoactive practices have become increasingly visible in discussions of mental health, cognition, creativity, emotional regulation, pain, sleep, spirituality, and psychological flexibility. However, the term microdosing is often used as if it referred to a single pharmacological phenomenon. More precisely, it describes a low-dose application pattern used across substances with different receptor mechanisms, experiential profiles, therapeutic hypotheses, evidence levels, and safety considerations. This article presents a conceptual and comparative review of psychedelic and psychedelic-adjacent low-dose psychoactive use. It examines classical psychedelics, dissociatives, empathogens, monoamine oxidase inhibitor-containing preparations, non-serotonergic mushroom-derived compounds, natural psychoactive matrices, isolated or synthetic pharmacological comparators, supplement-stacked practices, and relevant co-use variables. Rather than evaluating these substances through generalized assumptions of either benefit or harm, the article classifies them according to therapeutic plausibility, pharmacological mechanism, dose-response relationship, perceptibility, tolerance, neuroplasticity, contextual modulation, interaction potential, product standardization, natural-matrix complexity, and strength of evidence. The article argues that such classification is not optional but necessary. Without separating substance class, material form, dose-response, perceptibility, context, co-use, and evidence strength, microdosing research cannot produce interpretable or scientifically meaningful conclusions.